Inhibition of the BCR-ABL oncoprotein with imatinib in BCR-ABL-positive leukaemia cells resulted in decreased glucose uptake, lactate production and improved cellular energetics (Gottschalk et al, 2004), which were not recorded in their imatinib-resistant counterpart (Kominsky et al, 2009). This evidence concerns the gene ABL1 and leukemia.